|
Market Closed -
01:30:00 23/10/2026 am IST
|
5-day change
|
1st Jan Change
|
|
2.570 USD
|
0.00%
|
 |
-1.53%
|
+42.78%
|
|
16/09 |
Protalix BioTherapeutics, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-16-2026 01:05 PM
| | |
08/09 |
Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences
|
PR
| |
12/08 |
Protalix BioTherapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026
| | |
12/08 |
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
|
CI
| |
12/08 |
Protalix: Q2 Earnings Snapshot
|
AQ
| |
12/08 |
Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results
|
PR
| |
12/08 |
Protalix BioTherapeutics, Inc. Reaffirms Earnings Guidance for the Year 2026
|
CI
| |
05/08 |
Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026
|
PR
| |
13/05 |
Protalix BioTherapeutics, Inc., Q1 2026 Earnings Call, May 13, 2026
| | |
13/05 |
Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
|
CI
| |
13/05 |
Protalix BioTherapeutics : PLX Corporate Presentation (May 2026)
|
PU
| |
13/05 |
Protalix: Q1 Earnings Snapshot
|
AQ
| |
13/05 |
Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results
|
PR
| |
13/05 |
Protalix BioTherapeutics, Inc. Reaffirms Revenue Guidance for the Year 2026
|
CI
| |
06/05 |
Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026
|
PR
| |
19/03 |
Chiesi Global Rare Diseases and Protalix Biotherapeutics Announces European Commission Approval of an Add-On Every Four Weeks Dosing Regimen for Pegunigalsidase Alfa
|
CI
| |
18/03 |
Top Midday Decliners
|
MT
| |
18/03 |
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
|
CI
| |
18/03 |
Protalix BioTherapeutics, Inc., 2025 Earnings Call, Mar 18, 2026
| | |
18/03 |
Protalix BioTherapeutics, Inc. Provides Earnings Guidance for the Year 2026
|
CI
| |
18/03 |
Protalix Biotherapeutics reports fiscal year 2025 financial and business results
|
RE
| |
18/03 |
Protalix: Q4 Earnings Snapshot
|
AQ
| |
18/03 |
Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results
|
PR
| |
11/03 |
Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026
|
PR
| |
09/03 |
EU approves four-week dosing option for Chiesi and Protalix's Elfabrio
|
RE
|
Become a member to access more news New memberNo results match your criteria Select your edition All financial news and data tailored to specific country editions | 
